The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2025 | The efficacy of glofitamab in patients with heavily pre-treated R/R MCL
In this video, Tycel Phillips, MD, City of Hope, Duarte, CA, discusses the efficacy of glofitamab in patients with heavily pre-treated relapsed/refractory (R/R) mantle cell lymphoma (MCL), highlighting an impressive durability of response comparable to CAR T-cell products. Dr Phillips notes that a Phase III study of glofitamab versus investigator’s choice is underway. This interview took place at the 13th Annual Meeting of the Society of Hematologic Oncology (SOHO 2025) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
The 179 study which looked at glofitamab and various B-cell malignancies, we did have a cohort of patients with mantle cell lymphoma. We found from this data set that with the use of Obinutuzumab pretreatment at two grams and following up with step-up dosing of glofitamab and then glofitamab every three weeks for 12 cycles, we were able to demonstrate impressive efficacy in this patient population...
The 179 study which looked at glofitamab and various B-cell malignancies, we did have a cohort of patients with mantle cell lymphoma. We found from this data set that with the use of Obinutuzumab pretreatment at two grams and following up with step-up dosing of glofitamab and then glofitamab every three weeks for 12 cycles, we were able to demonstrate impressive efficacy in this patient population. More specifically, what we see is that patients who are able to obtain a complete remission and that remission remains at the end of treatment, most of these patients will have some durability of a response that appears to be quite impressive and on par with what we see with CAR T-cell products such as brexu-cel. Unfortunately, during the conduction of the study, it was obviously during the pandemic, we had issues with some patients passing away. We had seven patients who died in a complete response due to the COVID virus, which unfortunately has impacted some of the long-term efficacy assessments. But the data itself was sufficient and impressive enough that we’ve embarked on a phase three study of glofitamab in this patient population versus investigator’s choice. And we’ll look forward to seeing how this study reads out and hopefully this will lead to an approval for this drug in this patient population as another option for our patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
